Treating Adult Women With Depression Through Videoconferencing

The occurrence of depression in the United States is steadily increasing. In every age group, women have a higher rate of depression than men, and U.S. women between the ages of 40 and 59 have a depression rate of 12%. Adult women living in rural areas experience physical and/or psychological impairment and lack access to mental health treatment. The purpose of this quantitative nonexperimental study was to examine participants\u27 preferences for treatment delivery method based on patient perceptions of the clinical experience, patient satisfaction, and therapeutic bond. The working alliance theory provided the theoretical foundation. Data collection included survey responses from a self-selected sample of 264 adult females ages 40 to 65. Results from independent sample t tests indicated that participants favored CBT treatment delivered via videoconferencing more than in-person treatment. Implications for social change include improving the lives of adult women suffering from depression by providing treatment via videoconferencing when in-person services are not available. Psychologists may apply findings in clinical practice, thereby benefiting individuals, families, and communities

Kompozicinio deflokulianto poveikis ugniai atsparaus betono struktūrai ir savybėms

Disertacijoje nagrinėjami ugniai atsparaus lietinio betono savybės su skirtingais deflokuliantų priedais. Pagrindiniai tyrimo objektai: ugniai atspari rišamoji medžiaga ir ugniai atsparūs betonai su kompoziciniu deflokuliantu. Pastaruoju metu, kuriant naujus kaitrai atsparius betonus ir tobulinant jų gamybos technologiją, pradėti taikyti „naujos kartos“ polikarbokslilatinių esteriu pagrindu sukurti deflokuliantai, įvairūs ultradispersinių ir cheminių priedų mišiniai, pasižymintys ne tik deflokuliuojančiomis, bet ir struktūros susidarymą reguliuojančiomis savybėmis. Tačiau struktūros susidarymo veikimo mechanizmas nėra išsamiai ištirtas, todėl sėkmingas deflokuliantų taikymas reikalauja specialių sąlygų ir paruoštų aukštos kokybės ugniai atsparių betonų komponentų. Šie tyrimai svarbūs ne tik medžiagotyros teoriniams pagrindams pagilinti, bet ir statybų pramonės uždaviniams spręsti. Pagrindinis disertacijos tikslas – ištirti kompozicinio deflokulianto poveikio mechanizmą ugniai atsparaus betono rišiklio struktūrai ir sukurti geresnėmis stipruminėmis savybėmis pasižymintį ilgaamžišką ugniai atsparų betoną. Naudojant disertacijoje aprašytą tyrimų metodiką, sprendžiami šie pagrindiniai uždaviniai: skirtingo tipo pavienių ir kompozicinių deflokuliuojančių priedų poveikio ypatumai ugniai atspariai rišamajai medžiagai, susidedančiai iš aliuminatinio cemento ir SiO2 mikrodulkių, hidratacijos procesams ir struktūros formavimuisi ir kompozicinių deflokuliuojančių priedų poveikio sukurto ugniai atsparaus lietinio betono fizikinėms ir mechaninėms savybėms dėsningumai Disertaciją sudaro įvadas, trys skyriai, bendrosios išvados, naudotos literatūros ir autoriaus publikacijų disertacijos tema sąrašai. Įvadiniame skyriuje aptariama tiriamoji problema, darbo aktualumas, aprašomas tyrimų objektas, formuluojamas darbo tikslas bei uždaviniai, darbo mokslinis naujumas, darbo rezultatų praktinė reikšmė, ginamieji teiginiai. Įvado pabaigoje pristatomos disertacijos tema autoriaus paskelbtos publikacijos ir pranešimai konferencijose bei disertacijos struktūra. Pirmasis skyrius skirtas literatūros analizei. Jame pateikta ugniai atsparių lietinių betonų ir skirtingo tipo deflokuliantų apžvalga. Antrajame skyriuje pateiktas žaliavų aprašymas ir tyrimų metodikos. Trečiajame skyriuje tiriamas deflokuliantų poveikis ugniai atsparios rišamosios medžiagos struktūrai ir ugniai atsparaus betono fizikinėms ir mechaninėms savybėms bei nustatomi dėsningumai, leidžiantys prognozuoti ugniai atsparaus betono stiprumines ir kitas savybes. Disertacijos tema paskelbti septyni straipsniai, iš jų trys – straipsnių rinkiniuoe, įtrauktuose į Thomson ISI sąrašą. Disertacijos tema perskaityti septyni pranešimai Lietuvos bei kitų šalių konferencijose

STIMULATION OF INTELLECTUAL INNOVATION OF MANAGERIAL STAFF

Research goal: The aim of the reported study is to develop a methodology for encouraging intellectual innovation among managerial staff, taking into account the individual labor participation of the employee, which would provide scientific validity in the allocation of the wage fund. Results: The authors propose a methodology for a comprehensive quantitative assessment of the innovation potential of middle and senior management of the organization with consideration of intelligence, creativity, and enterprise. Conclusion: The integral coefficient proposed in the paper reflects the excess of the basic cost estimate of the human capital of an employee, corresponding to the intellectual and qualification level, over the basic cost estimate of the human capital of the smaller/lower intellectual and qualification level of the professional qualification group

Рутениевые катализаторы на углеродном носителе с контролируемым размером частиц для селективного гидрирования левулиновой кислоты в γ-валеролактон

Liquid phase levulinic acid hydrogenation into γ-valerolactone in 1,4-dioxane as a solvent (165°C, 20 bar) was studied over a range of Ru monometallic catalysts using mesoporous carbon material Sibunit as a support. In addition to the catalyst prepared by impregnation with RuCl3∙nH2O (0.1 M) followed by reduction in H2, size-controlled Ru(NPs)/Sibunit catalysts were synthesized by immobilization of polyvinylpyrrolidone (PVP) stabilized Ru nanoparticles (NPs) (dRu=2.4 nm). Сarbon supported colloidal Ru NPs were not studied earlier in levulinic acid hydrogenation. Activity of colloidal Ru(NPs)/Sibunit catalysts was found to be lower than that of impregnated Ru/Sibunit which could be attributed to hampering effect of PVP. However, colloidal Ru(NPs)/Sibunit purified by thermal treatment in air (180°C) followed by reduction in H2 (400°C) exhibited the same activity as impregnated one yielding 93% γ-valerolactone at 100% levulinic acid conversion. Applicability of supported PVP-assisted colloidal Ru NPs in hydrogenation of levulinic acid illustrates a potential to prepare more efficient catalysts for this reaction with a desired particle size. The catalysts were characterized by TEM, XRF, and N2 physisorption to compare their physical chemical propertiesЖидкофазное гидрирование левулиновой кислоты (ЛК) в γ-валеролактон (ГВЛ) было изучено в присутствии Ru на мезопористом углеродном носителе Сибунит (растворитель 1,4-диоксан, 165 °C, давление водорода 20 бар). Наряду с катализаторами, приготовленными методом пропитки раствором RuCl3 nH2O (0,1 М) с последующим восстановлением в Н2, были синтезированы катализаторы Ru/Сибунит с контролируемым размером частиц Ru путем иммобилизации стабилизированных поливинилпирролидоном (ПВП) наночастиц (НЧ) Ru (dRu 2,4 нм), ранее не исследованные в гидрировании ЛК. Показано, что активность коллоидных Ru(НЧ)/Сибунит ниже, чем у пропиточных, что может быть обусловлено блокирующим эффектом ПВП. Обработка на воздухе (180 °C) с последующим восстановлением в водороде (400 °C) приводит к увеличению активности Ru(НЧ)/Сибунит до активности пропиточного Ru/Сибунит с селективностью 93 % по ГВЛ при 100%-й конверсии ЛК. Эффективность ПВП- стабилизированных коллоидных НЧ Ru в гидрировании ЛК открывает возможность получения более эффективных катализаторов для этой реакции с контролируемым размером частиц. Катализаторы изучены методами ПЭМ, РФлА и адсорбции азот

Aneuploidy and Confined Chromosomal Mosaicism in the Developing Human Brain

BACKGROUND: Understanding the mechanisms underlying generation of neuronal variability and complexity remains the central challenge for neuroscience. Structural variation in the neuronal genome is likely to be one important mechanism for neuronal diversity and brain diseases. Large-scale genomic variations due to loss or gain of whole chromosomes (aneuploidy) have been described in cells of the normal and diseased human brain, which are generated from neural stem cells during intrauterine period of life. However, the incidence of aneuploidy in the developing human brain and its impact on the brain development and function are obscure. METHODOLOGY/PRINCIPAL FINDINGS: To address genomic variation during development we surveyed aneuploidy/polyploidy in the human fetal tissues by advanced molecular-cytogenetic techniques at the single-cell level. Here we show that the human developing brain has mosaic nature, being composed of euploid and aneuploid neural cells. Studying over 600,000 neural cells, we have determined the average aneuploidy frequency as 1.25-1.45% per chromosome, with the overall percentage of aneuploidy tending to approach 30-35%. Furthermore, we found that mosaic aneuploidy can be exclusively confined to the brain. CONCLUSIONS/SIGNIFICANCE: Our data indicates aneuploidization to be an additional pathological mechanism for neuronal genome diversification. These findings highlight the involvement of aneuploidy in the human brain development and suggest an unexpected link between developmental chromosomal instability, intercellural/intertissular genome diversity and human brain diseases

Diabetes mellitus type 2 in adults

Public organization “Russian Association of Endocrinologists”. Clinical guidelines.&nbsp

Diabetes mellitus type 1 in adults

Public organization “Russian Association of Endocrinologists”. Clinical guidlines

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p<0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (<1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (<1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline

Biological Earth observation with animal sensors

Space-based tracking technology using low-cost miniature tags is now delivering data on fine-scale animal movement at near-global scale. Linked with remotely sensed environmental data, this offers a biological lens on habitat integrity and connectivity for conservation and human health; a global network of animal sentinels of environmen-tal change

Improving the Classification Quality of the SVM Classifier for the Imbalanced Datasets on the Base of Ideas the SMOTE Algorithm

The approach to the classification problem of the imbalanced datasets has been considered. The aim of this research is to determine the effectiveness of the SMOTE algorithm, when it is necessary to improve the classification quality of the SVM classifier, which is applied for classification of the imbalanced datasets. The experimental results which demonstrate the improvement of the SVM classifier quality with application of ideas the SMOTE algorithm for the imbalanced datasets in the sphere of medical diagnostics have been given